Livanova USA Inc.

Livanova USA Inc., a Houston-based for-profit manufacturer of medical devices, sells neurostimulation generators, cardiac perfusion equipment, surgical implants, and related maintenance services to federal healthcare agencies as a prime contractor on full-and-open purchase orders, competing without set-aside designations as a large business.

Livanova specializes in implantable neurological and cardiovascular technologies. The vendor's product portfolio encompasses vagus nerve stimulation therapy systems for epilepsy treatment, Sentiva neurostimulators, heart-lung bypass machines and perfusion systems, spinal and prosthetic surgical implants, and authorized maintenance and repair services for proprietary equipment the company manufactures. Representative contracts include a $468 thousand equipment maintenance contract with Veterans Integrated Service Network 8 (awarded February 2026, ultimate completion February 2031) for Tampa-area facilities, a $431 thousand cardiopulmonary maintenance services contract with VISN 10 (awarded February 2026) at the Louis Stokes Cleveland VA Medical Center, a $306 thousand repair and preventative maintenance contract with VISN 7 (awarded August 2026) for Livanova S5 heart-lung bypass machines at Ralph H. Johnson VA Medical Center, and a $426 thousand base-year heart-lung equipment contract with VISN 22 (awarded October 2025) in San Diego. The majority of awards are firm fixed-price purchase orders for individual device units, typically ranging from $30 thousand to $50 thousand.

Customer concentration reflects heavy reliance on military and veteran healthcare. The Defense Health Agency leads by dollar value with 73 awards worth $19.4 million combined potential value; the Department of the Army Medical Command places 87 awards worth $8.1 million; and the Department of the Navy Bureau of Medicine and Surgery holds 171 awards worth $4.9 million. Veterans Affairs networks collectively account for substantial volume—VISN 6, VISN 10, VISN 19, VISN 2, VISN 15, and VISN 8 are among the top ten funding sources by count and dollars. The top five customers by potential value (Defense Health Agency, Army Medical Command, Navy Bureau of Medicine and Surgery, VISN 19, and VISN 2) collectively account for 61 percent of combined potential value.

Livanova holds three named parent vehicles. A $6.5 million Blanket Purchase Agreement with the Defense Health Agency (HT001421A0015, established 2021) is the most strategically significant, with four task orders totaling $483 thousand placed to date; this vehicle is the foundation for VNS therapy system procurements supporting epilepsy treatment at military medical facilities. An Indefinite Delivery Contract with the Department of the Army (W81K0007A0016) carries 23 task orders worth $438 thousand. A second Defense Health Agency BPA (HT001416A0073) shows 11 task orders valued at $2.1 million.

Activity has been relatively stable. The vendor received 30 awards in 2022, 33 in 2023, 38 in 2024, declining to 19 in 2025 and 18 in 2026 through September. Combined potential value across the 904 prime awards in the source is $61.2 million, with $34.9 million obligated (57 percent). Only eight awards with ultimate completion in the next twenty-four months total $782 thousand in potential value, creating minimal near-term recompete pressure. Over the broader portfolio, NAICS concentration is highest in electromedical and electrotherapeutic apparatus manufacturing (343 awards) and surgical appliance and supplies manufacturing (258 awards); PSC concentration is overwhelming under Medical and Surgical Instruments, Equipment, and Supplies (828 of 904 awards). Livanova has served 29 distinct federal customer agencies, though the top five dominate both by award count and dollar value. The vendor operates exclusively as a prime contractor with no subcontract footprint reflected in the source data, meaning all 904 awards represent direct delivery from Livanova to customer agencies.